Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Cp-jeez! Aza-natomy!

Suarez L, Gore SD.

Blood. 2012 Sep 20;120(12):2354-5.

2.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Estey EH.

Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12. Review.

PMID:
23757301
3.

Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.

Aparicio A, Weber JS.

Curr Opin Investig Drugs. 2002 Apr;3(4):627-33. Review.

PMID:
12090735
4.

The role of hypomethylating agents in the treatment of elderly patients with AML.

Al-Ali HK, Jaekel N, Niederwieser D.

J Geriatr Oncol. 2014 Jan;5(1):89-105. doi: 10.1016/j.jgo.2013.08.004. Epub 2013 Sep 24. Review.

6.
7.

[Progress in research on DNA methylation and laryngeal carcinoma].

Liu Y, Liu HG.

Zhonghua Bing Li Xue Za Zhi. 2011 Jan;40(1):67-70. Review. Chinese. No abstract available.

PMID:
21429368
8.

[Research progress of epigenetic drug decitabine in AML].

Zhang R, Li HM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1467-71. doi: 10.7534/j.issn.1009-2137.2014.05.054. Review. Chinese.

PMID:
25338609
9.

Pharmacokinetic evaluation of decitabine for the treatment of leukemia.

Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):661-72. doi: 10.1517/17425255.2011.575062. Review.

PMID:
21500965
10.

Use of hypomethylating agents in myelodysplastic syndromes.

Atallah E, Garcia-Manero G.

Clin Adv Hematol Oncol. 2007 Jul;5(7):544-52. Review.

PMID:
17679928
11.

DNA methylation: its role in cancer development and therapy.

Kurkjian C, Kummar S, Murgo AJ.

Curr Probl Cancer. 2008 Sep-Oct;32(5):187-235. doi: 10.1016/j.currproblcancer.2008.08.002. Review. No abstract available.

Supplemental Content

Support Center